How Fosamax Triggers Osteonecrosis of the Jaw: Pathophysiology and Causation

Latest update (2026-05)

FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]

From General Health Principles to Specific Occupational Exposures

The legacy of general health and science information has long emphasized broad preventive measures and public awareness, focusing on lifestyle factors, nutrition, and common disease prevention. This foundation provides a baseline for understanding how various exposures might influence health outcomes. Within this context, the transition from general health principles to more specific occupational concerns requires careful consideration of how routine industrial processes can introduce unique risk factors. As manufacturing environments often involve repeated handling of chemical compounds and materials, the potential for unintended health effects becomes a relevant extension of general health knowledge. The shift from a broad informational heritage to a focused occupational exposure concern is marked by the need to identify specific agents that may be encountered in production settings. This pivot does not delve into mechanistic pathways but rather acknowledges that certain substances, when present in the workplace, warrant heightened awareness. The legacy of general health science thus serves as a springboard for recognizing that occupational contexts can amplify or modify risks that are otherwise managed in everyday life. This transition sets the stage for examining how specific exposures, such as those related to pharmaceutical manufacturing or material handling, may intersect with worker health, without yet specifying any particular disease or causal mechanism.

Bridging to Fosamax and Osteonecrosis of the Jaw

Building on the recognition that occupational and pharmaceutical exposures can introduce unique health risks, we now focus on a specific medication: Fosamax (alendronate). Fosamax is a bisphosphonate approved for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Its use has been associated with a serious adverse effect: osteonecrosis of the jaw (ONJ). Understanding the pathophysiology of how Fosamax triggers ONJ requires examining the drug's pharmacology, the unique characteristics of jawbone tissue, and the clinical circumstances under which ONJ develops.

Pharmacology of Fosamax and Its Anti-Resorptive Action

Fosamax belongs to the class of bisphosphonates, which work by inhibiting bone resorption. This mechanism is beneficial for increasing bone mass and reducing fracture risk in osteoporosis patients (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). However, the same anti-resorptive action can disrupt normal bone turnover in the jaw. The jawbone has distinct structural and metabolic properties compared to other skeletal sites. Multiscale characterization of jawbone treated with osteoporosis therapeutic agents has provided information that helps understand jawbone-specific responses to bone-related complications, including bisphosphonate-related osteonecrosis of the jaw (https://pubmed.ncbi.nlm.nih.gov/40345077/). This research indicates that bisphosphonate treatment, including alendronate (the active ingredient in Fosamax), can alter the mechanical stability of teeth in the alveolar socket, tissue mineral density distribution, and nanoindentation properties of the jawbone matrix (https://pubmed.ncbi.nlm.nih.gov/40345077/). These changes may predispose the jawbone to necrosis.

Pathophysiology of Fosamax-Induced Osteonecrosis of the Jaw

The pathophysiology of Fosamax-induced ONJ is believed to involve several interconnected mechanisms. First, bisphosphonates accumulate in bone, particularly at sites of high turnover such as the jaw. By suppressing osteoclast activity, Fosamax reduces the normal remodeling process that repairs microdamage and maintains bone health. Over time, this suppression can lead to the accumulation of microdamage and a loss of bone viability. Second, bisphosphonates may have anti-angiogenic effects, reducing blood supply to the jawbone. The combination of reduced bone turnover and impaired vascularity creates an environment where the bone cannot adequately respond to injury or infection. Clinically, ONJ associated with Fosamax is generally associated with tooth extraction and/or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Known risk factors for ONJ include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (e.g., periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection, ill-fitting dentures) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk of ONJ may increase with duration of exposure to bisphosphonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). For patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

Clinical Evidence and Causation Considerations

The time to onset of symptoms varied from one day to several months after starting the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Most patients had relief of symptoms after stopping the drug, but a subset had recurrence of symptoms when rechallenged with the same drug or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). In placebo-controlled clinical studies of Fosamax, the percentages of patients with these symptoms were similar in the Fosamax and placebo groups (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This suggests that while ONJ is a recognized adverse effect, its incidence in clinical trials was low and not statistically different from placebo, indicating that other factors, such as underlying dental disease or invasive procedures, play a significant role in triggering the condition. Causation considerations for affected patients involve evaluating the timeline between Fosamax exposure and the development of ONJ. The onset can be rapid (one day) or delayed (several months), and the condition can occur spontaneously, though it is generally associated with dental procedures or infection (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The adequacy of warnings regarding Fosamax and ONJ is addressed in the drug's labeling, which includes a specific section on osteonecrosis of the jaw (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The label notes that ONJ has been reported in patients taking bisphosphonates, including Fosamax, and lists known risk factors (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). However, the label also states that in placebo-controlled studies, the percentages of patients with symptoms were similar in the Fosamax and placebo groups (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This information may influence how patients and clinicians weigh the risk of ONJ against the benefits of Fosamax for osteoporosis treatment.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the primary mechanism by which Fosamax causes osteonecrosis of the jaw?

Fosamax (alendronate) suppresses osteoclast activity, reducing bone turnover and repair of microdamage. This, combined with potential anti-angiogenic effects that impair blood supply, creates an environment where the jawbone cannot adequately respond to injury or infection, leading to necrosis.

What are the known risk factors for developing ONJ while taking Fosamax?

Risk factors include invasive dental procedures (tooth extraction, implants, boney surgery), cancer diagnosis, concomitant therapies (chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders such as periodontal disease, anemia, coagulopathy, infection, and ill-fitting dentures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

How long after starting Fosamax can ONJ symptoms appear?

The time to onset of symptoms can vary from one day to several months after starting the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Fosamax exposure and a confirmed Osteonecrosis of the Jaw diagnosis may request an independent eligibility review. [Begin Assessment]

References

Check Whether Your Situation Qualifies

Free and confidential. No obligation — an initial records screening only.

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.